Showing results (1-10 of 171) with videos related to
Sort By:
Pageof 18
Metabolism: Clinical and Experimental|September 23, 2014
Diabetic dyslipidemiaLiya Wu, Klaus G ParhoferPlos One|March 23, 2022
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)Elisa Waldmann, Liya Wu, Kristina Busygina, et al.Current Pharmaceutical Design|April 12, 2011
Lipoprotein(a): medical treatment options for an elusive moleculeKlaus G ParhoferRevista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|October 12, 2018
CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUSKlaus G ParhoferCurrent Opinion in Lipidology|September 14, 2017
New approaches to address dyslipidemiaKlaus G ParhoferCurrent Atherosclerosis Reports|January 26, 2023
Apheresis: What Should a Clinician Know?Klaus G ParhoferInnere Medizin (Heidelberg, Germany)|June 15, 2023
[Update lipidology : Evidence-based treatment of dyslipidemia]Klaus G ParhoferCurrent Atherosclerosis Reports|October 14, 2021
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?Klaus G ParhoferCore Evidence|June 16, 2012
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemiaKlaus G ParhoferDeutsches Arzteblatt International|May 7, 2016
The Treatment of Disorders of Lipid MetabolismKlaus G ParhoferPageof 18